The Clinical Research Office Shared Resource (CRO) oversees the review, initiation, conduct, and safety monitoring of clinical trials at the Norris Cotton Cancer Center. The CRO components are 1) an administrative staff including the Shared Resource Director, an Associate Director, an Assistant Director, a financial manager, and a protocol assistant; 2) the Protocol-Specific Research Support staff, comprising a research pharmacist, a pharmacy technician, two research registered nurses, and 16 clinical research assistants / coordinators; 3) the Protocol Review and Monitoring System, consisting of the Clinical Cancer Research Committee (CCRC) and the Safety and Data Monitoring Committee (SDMC); and 4) the Dartmouth-Hitchcock Tumor Registry, staffed by three registrars. Although DHMC and the NCCC have designated the CRO as the office responsible for administrative oversight of all aspects of clinical cancer research including the hospital tumor registry, our request for CCSG funding is for the more narrowly defined functions of this Shared Resource related to support peer-reviewed clinical trials of cancer treatment and chemoprevention. The CRO maintains local Dartmouth Medical School studies, working group studies, cooperative group protocols, and industrial trials. It is responsible for assisting in formatting protocols, writing consent forms, maintaining Institutional Review Board and SDMC records, developing budgets, assessing impact on institutional resources, activating protocols, assessing eligibility, developing data collection forms and databases, and collecting and managing data. Prioritization of clinical trials is determined within the 12 NCCC Clinical Oncology Groups, with approval by the CCRC. The CRO acts as a checkpoint prior to activation of protocols to ensure that all appropriate administrative aspects of trials are complete. Charge-back policies of the CRO accurately reflect usage, and are based on patient accrual to reviewed and approved protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023108-26
Application #
6989460
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-07-02
Project End
2008-11-30
Budget Start
2004-07-02
Budget End
2004-11-30
Support Year
26
Fiscal Year
2004
Total Cost
$87,662
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Bronson, Mackenzie R; Kapadia, Nirav S; Austin, Andrea M et al. (2018) Leveraging Linkage of Cohort Studies With Administrative Claims Data to Identify Individuals With Cancer. Med Care 56:e83-e89
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Hancock, D B; Guo, Y; Reginsson, G W et al. (2018) Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. Mol Psychiatry 23:1-9
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346
Gorlov, Ivan; Orlow, Irene; Ringelberg, Carol et al. (2018) Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. Melanoma Res 28:380-389
Shiner, Brian; Westgate, Christine Leonard; Gui, Jiang et al. (2018) A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice. J Clin Psychiatry 79:
Wu, Wenting; 23andMe Research Team; Amos, Christopher I et al. (2018) Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk. J Invest Dermatol 138:2072-2075
Downey-Kopyscinski, Sondra; Daily, Ellen W; Gautier, Marc et al. (2018) An inhibitor of proteasome ?2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2:2443-2451
Varn, Frederick S; Tafe, Laura J; Amos, Christopher I et al. (2018) Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. Oncoimmunology 7:e1431084

Showing the most recent 10 out of 1911 publications